Elisa Agostinetto: FDA has approved ribociclib with an AI for the adjuvant treatment of HR+/HER2-negative breast cancer

Elisa Agostinetto shared a post on X:

“Novartis today announced that the FDA has approved ribociclib in combination with an AI for the adjuvant treatment of HR+/HER2-neg stage II-III EBC based on the results of NATALEE presented at ESMO24.”

Source: Elisa Agostinetto/X

Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.